Drugs / FCARH143
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03338972 | Nov 2017 → May 2021 | plasma cell myeloma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FCARH143 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03338972 ↗ |
| Action | Deplete | “may kill cancer cells with the protein BCMA on their surface.” NCT03338972 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor (CAR) T-cell (CAR-T) therapy” PMID 40198877 ↗ Jul 2025 |
| Route | Intravenous | “Given IV” NCT03338972 ↗ |